Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Joseph A. Sparano, MD, of Montefiore Medical Center, discuss this study of high-risk premenopausal luminal A breast cancer patients receiving adjuvant chemotherapy (Abstract S1-08).
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Erica L. Mayer, MD, MPH, of the Dana-Farber Cancer Institute, discuss this phase 3 trial of palbociclib with adjuvant endocrine therapy vs endocrine therapy alone for HR-positive/HER2-negative early breast cancer. (Abstract OT1-03-21)
William M. Sikov, MD, of Women and Infants Hospital of Rhode Island, discusses the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).
Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation in early breast cancer (Abstract S3-07).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Carlos L. Arteaga, MD, of Vanderbilt University, discuss the roles of IGF/insulin signaling, adipokines and inflammation, and metformin and lifestyle change in breast cancer and risk for the disease.
